ArticlePloS one2014
EGFR, HER-2 and KRAS in canine gastric epithelial tumors: a potential human model?
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 44 citations in OpenAlex.
- Review
- Effects of trastuzumab emtansine on canine osteosarcoma cells.The Journal of veterinary medical science · 2025Article
- Immunohistochemical Expression of Human Epidermal Growth Factor Receptor 2 and Ki67 in Apocrine Gland Anal Sac Adenocarcinoma.International journal of molecular sciences · 2024Article
- A Preliminary Evaluation of the Prognostic Role of HER-2 and HER-3 Immunohistochemical Expression in Canine Melanomas.Animals : an open access journal from MDPI · 2024Article
- An evaluation of the combination effect of zoledronate and chemotherapeutic agents in canine osteosarcoma cells.Frontiers in veterinary science · 2024Article
- Research progress on exosomal proteins as diagnostic markers of gastric cancer (review article).Clinical and experimental medicine · 2023Review
- E-cadherin Expression in Canine Gastric Carcinomas: Association with Clinicopathological Parameters.Veterinary sciences · 2022Article
- Immunoexpression of Trefoil Factor 1 in Non-Neoplastic and Neoplastic Canine Gastric Tissues.Animals : an open access journal from MDPI · 2021Article
- Immunohistochemical Screening of HER2 in Canine Carcinomas: A Preliminary Study.Animals : an open access journal from MDPI · 2021Article
- Gastric mucosal pathology in Belgian Shepherd dogs with and without clinical signs of gastric disease.Acta veterinaria Scandinavica · 2021Article
- Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells.BMC veterinary research · 2019Article
- Multistaining Optimization for Epstein-Barr Virus-Encoded RNA In Situ Hybridization and Immunohistochemistry of Formalin-Fixed Paraffin-Embedded Tissues Using an Automated Immunostainer.Journal of pathology and translational medicine · 2019Article
- Identifying Candidate Druggable Targets in Canine Cancer Cell Lines Using Whole-Exome Sequencing.Molecular cancer therapeutics · 2019Article
- Transcriptome Signatures of Canine Mammary Gland Tumors and Its Comparison to Human Breast Cancers.Cancers · 2018Article
- Combined effects of EGFR and hedgehog signaling blockade on inhibition of head and neck squamous cell carcinoma.International journal of clinical and experimental pathology · 2017Article
- Tumor suppressor microRNA-31 inhibits gastric carcinogenesis by targeting Smad4 and SGPP2.Cancer gene therapy · 2015Article
- Correction: EGFR, HER-2 and KRAS in canine gastric epithelial tumors: a potential human model?PloS one · 2015Article
- Article
- Knockdown of EGFR inhibits growth and invasion of gastric cancer cells.Cancer gene therapy · 2014Article
Corrections and comments
- Erratum issued
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epidermal growth factor receptor (EGFR or HER-1) and its analog c-erbB-2 (HER-2) are protein tyrosine kinases correlated with prognosis and response to therapy in a variety of human cancers. KRAS mediates the transduction of signals between EGFR and the nucleus, and its mutation has been identified as a predictor of resistance to anti-EGFR drugs. In human oncology, the importance of the EGFR/HER-2/KRAS signalling pathway in gastric cancer is well established, and HER-2 testing is required before initiating therapy. Conversely, this pathway has never been investigated in canine gastric tumours. A total of 19 canine gastric epithelial neoplasms (5 adenomas and 14 carcinomas) were retrospectively evaluated for EGFR/HER-2 immunohistochemical expression and KRAS mutational status. Five (35.7%) carcinomas were classified as intestinal-type and 9 (64.3%) as diffuse-type. EGFR was overexpressed (≥ 1+) in 8 (42.1%) cases and HER-2 (3+) in 11 (57.9%) cases, regardless of tumour location or biological behaviour. The percentage of EGFR-positive tumours was significantly higher in the intestinal-type (80%) than in the diffuse-type (11.1%, p = 0.023). KRAS gene was wild type in 18 cases, whereas one mucinous carcinoma harboured a point mutation at codon 12 (G12R). EGFR and HER-2 may be promising prognostic and therapeutic targets in canine gastric epithelial neoplasms. The potential presence of KRAS mutation should be taken into account as a possible mechanism of drug resistance. Further studies are necessary to evaluate the role of dog as a model for human gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.